3-{[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl}-4,5-dihydro-1H-1,2,4-triazol-5-one

• ChemBase编号: 72569
• 分子式: C23H21F7N4O3
• 平均质量: 534.4266624
• 单一同位素质量: 534.15018809
• SMILES: n1[nH]c(=O)[nH]c1CN1[C@H]([C@H](OCC1)O[C@H](C)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)c1ccc(cc1)F
• Canonical SMILES: Fc1ccc(cc1)[C@H]1[C@H](OCCN1Cc1n[nH]c(=O)[nH]1)O[C@@H](c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C
• InChI: InChI=1S/C23H21F7N4O3/c1-12(14-8-15(22(25,26)27)10-16(9-14)23(28,29)30)37-20-19(13-2-4-17(24)5-3-13)34(6-7-36-20)11-18-31-21(35)33-32-18/h2-5,8-10,12,19-20H,6-7,11H2,1H3,(H2,31,32,33,35)/t12-,19+,20-/m1/s1
• InChIKey: ATALOFNDEOCMKK-OITMNORJSA-N

名称和登记号

名称

• IUPAC标准名: 3-{[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl}-4,5-dihydro-1H-1,2,4-triazol-5-one
• IUPAC传统名: aprepitant; @aprepitant
• 别名: 5-[[(2R,3S)-2-[(1R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one; L 754030; MK 0869; MK 869; ONO 7436; MK-869; L-754030; Emend; ); Aprepitant

登记号

• CAS号: 170729-80-3
• PubChem SID: 162037494
• PubChem CID: 6918365

理论计算性质

• Acid pKa: 9.646593
• 质子受体: 5
• 质子供体: 2
• LogD (pH = 5.5): 5.211254
• LogD (pH = 7.4): 5.2134037
• Log P: 5.215729
• 摩尔折射率: 116.9282 cm^3
• 极化性: 43.315456 Å^3
• 极化表面积: 75.19 Å^2
• 可自由旋转的化学键: 8
• 里宾斯基五规则: false

分子性质

理化性质

• 溶解度: Chloroform; DMSO; Methanol
• 外观: White to Off-White Solid
• 熔点: 244-246°C

安全信息

• 保存条件: -20°C; -20°C Freezer

药理学性质

• 作用靶点: substance P

产品相关信息

• 成盐信息: Free Base

详细说明

Selleck Chemicals - S1189

Research Area: Neurological Disease
Biological Activity:
Aprepitant is an antiemetic chemical compound that belongs to a class of drugs called substance P antagonists (SPA). It mediates its effect by blocking the neurokinin 1 (NK1) receptor. Aprepitant is used for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) and for prevention of postoperative nausea and vomiting.[1]References on Aprepitant (MK-0869)[1] http://en.wikipedia.org/wiki/Aprepitant, ,

Toronto Research Chemicals - A729800

A novel selective neurokinin-1 (NK-1) receptor antagonist. In vitro studies using human liver microsomes indicate that Aprepitant is metabolised primarily by CYP3A4 with minor metabolism by CYP1A2 and CYP2C19, and no metabolism by CYP2D6, CYP2C9, or CYP2E

参考文献

• http://www.search.com/reference/Aprepitant
• Hale, J.J., et al.: J. Med. Chem., 41, 4607 (1998)
• Campos, D., et al.: J. Clin. Oncol., 19, 1759 (1998)
• Van Belle, S., et al.: Cancer, 94, 3032 (1998)
• Majumdar, A.K., et al.: J. Clin. Pharmacol., 46, 291 (1998)